We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+20.26%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.39B
AUM Growth
+$536M
Cap. Flow
+$459M
Cap. Flow %
32.88%
Top 10 Hldgs %
64.45%
Holding
40
New
9
Increased
6
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$90.2M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$56M
3
DYAX
DYAX CORPORATION
DYAX
+$52.9M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$27.8M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$20M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.3M
2
TXMD icon
TherapeuticsMD
TXMD
+$11.6M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$8.48M
4
ENZ
Enzo Biochem, Inc.
ENZ
+$6.62M
5
NVAX icon
Novavax
NVAX
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 58.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
PUT
Gilead Sciences
GILD
$165B
$170M 12.2%
+2,400,000
New +$188M
ACAD icon
2
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
$128M 9.16%
5,250,000
– –
SGMO
3
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$108M 7.78%
6,000,000
+3,000,000
+100% +$57.8M
SGMO
4
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$94.4M 6.77%
5,222,053
-5,219
-0.1% -$101K
ACHN
5
DELISTED
Achillion Pharmaceuticals
ACHN
$76.9M 5.51%
23,366,007
– –
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$68.6M 4.92%
+2,428,571
New +$90.2M
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
$66.8M 4.79%
7,436,470
+5,816,773
+359% +$52.9M
TXMD icon
8
TherapeuticsMD
TXMD
$23.8M
$62.1M 4.45%
196,769
-36,433
-16% -$11.6M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$62M 4.45%
1,737,856
+137,401
+9% +$4.63M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$362M
$61.6M 4.42%
+1,541,078
New +$56M
PRTA icon
11
Prothena Corp
PRTA
$448M
$59.6M 4.27%
1,554,918
-86,249
-5% -$2.78M
ARWR icon
12
Arrowhead Research
ARWR
$12.1B
$48.3M 3.46%
2,941,916
+892,696
+44% +$15.7M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.42B
$46M 3.3%
4,347,456
– –
NVAX icon
14
Novavax
NVAX
$1.21B
$45M 3.23%
496,913
-43,681
-8% -$4.88M
DVAX
15
DELISTED
Dynavax Technologies
DVAX
$32.3M 2.32%
1,788,395
– –
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$32.2M 2.31%
23,187
– –
XNCR icon
17
Xencor
XNCR
$1.45B
$32M 2.29%
2,725,000
– –
PTCT icon
18
PTC Therapeutics
PTCT
$6.18B
$25.7M 1.84%
981,761
+229,323
+30% +$6.16M
RPRX
19
DELISTED
Repros Therapeutics Inc.
RPRX
$25.5M 1.83%
+1,439,048
New +$27.8M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$20.6M 1.48%
700,000
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$18.8M 1.35%
+1,169,084
New +$20M
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$17M 1.22%
1,339,039
-655,837
-33% -$8.48M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.5M 0.9%
656,767
– –
BLUE
24
DELISTED
bluebird bio
BLUE
$10.6M 0.76%
36,085
– –
EYPT icon
25
EyePoint Inc
EYPT
$999M
$10.5M 0.75%
255,566
+136,805
+115% +$6.02M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, RA Capital Management held 40 positions worth $1.39B, up 62% from $858M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

RA Capital Management deployed $459M of net new capital in Q1 2014, opening 9 new positions and adding to 6 existing holdings. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 2,428,571 shares worth $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $23.3M trimmed.

  • RA Capital Management's largest Q1 2014 buy was Dicerna Pharmaceuticals, Inc.: 2,428,571 shares worth $68.6M.
  • RA Capital Management added most to DYAX CORPORATION in Q1 2014, an estimated $52.9M increase.
  • RA Capital Management's biggest Q1 2014 reduction was Acadia Pharmaceuticals, cutting an estimated $23.3M.
  • RA Capital Management fully exited Enzo Biochem, Inc. in Q1 2014, selling an estimated $6.62M.
  • RA Capital Management's ten largest holdings make up 64% of its $1.39B portfolio in Q1 2014.
  • RA Capital Management opened 9 new positions and closed 5 in Q1 2014.
  • RA Capital Management's portfolio value rose 62% quarter-over-quarter to $1.39B.

Based on RA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.